2029 Biosimilars Trials 
Vial
MARCH 1, 2024
Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market. billion by 2029. By revenue, the largest CRO in the US was Thermo Fisher Scientific Inc.,
Drug Discovery World
JULY 26, 2024
The strategy is aimed at keeping the sector competitive in a country that has recently been struggling to maintain relevance in the global medical device and clinical trials scenes. Conversely, Trump champions free market competition and biosimilars. Meanwhile, new cell therapies are showing promise in oncology.
Expert insights. Personalized for you.
52 
Let's personalize your content